Base de dados : MEDLINE
Pesquisa : D27.505.954.411.162 [Categoria DeCS]
Referências encontradas : 57391 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 5740 ir para página                         

  1 / 57391 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28844981
[Au] Autor:Gogineni V; Hamann MT
[Ad] Endereço:Department of BioMolecular Sciences, Division of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, MS, United States. Electronic address: vgoginen@go.olemiss.edu.
[Ti] Título:Marine natural product peptides with therapeutic potential: Chemistry, biosynthesis, and pharmacology.
[So] Source:Biochim Biophys Acta;1862(1):81-196, 2018 01.
[Is] ISSN:0006-3002
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The oceans are a uniquely rich source of bioactive metabolites, of which sponges have been shown to be among the most prolific producers of diverse bioactive secondary metabolites with valuable therapeutic potential. Much attention has been focused on marine bioactive peptides due to their novel chemistry and diverse biological properties. As summarized in this review, marine peptides are known to exhibit various biological activities such as antiviral, anti-proliferative, antioxidant, anti-coagulant, anti-hypertensive, anti-cancer, antidiabetic, antiobesity, and calcium-binding activities. This review focuses on the chemistry and biology of peptides isolated from sponges, bacteria, cyanobacteria, fungi, ascidians, and other marine sources. The role of marine invertebrate microbiomes in natural products biosynthesis is discussed in this review along with the biosynthesis of modified peptides from different marine sources. The status of peptides in various phases of clinical trials is presented, as well as the development of modified peptides including optimization of PK and bioavailability.
[Mh] Termos MeSH primário: Anti-Hipertensivos
Antineoplásicos
Antivirais
Organismos Aquáticos/química
Hipoglicemiantes
Biossíntese Peptídica
Peptídeos
[Mh] Termos MeSH secundário: Animais
Anti-Hipertensivos/química
Anti-Hipertensivos/uso terapêutico
Antineoplásicos/química
Antineoplásicos/uso terapêutico
Antivirais/química
Antivirais/uso terapêutico
Organismos Aquáticos/metabolismo
Seres Humanos
Hipoglicemiantes/química
Hipoglicemiantes/uso terapêutico
Peptídeos/química
Peptídeos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Antineoplastic Agents); 0 (Antiviral Agents); 0 (Hypoglycemic Agents); 0 (Peptides)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170829
[St] Status:MEDLINE


  2 / 57391 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465596
[Au] Autor:Chen B; Wang Y; He Z; Wang D; Yan X; Xie P
[Ad] Endereço:The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine.
[Ti] Título:Tianma Gouteng decoction for essential hypertension: Protocol for a systematic review and meta-analysis.
[So] Source:Medicine (Baltimore);97(8):e9972, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Essential hypertension is one of the most common chronic diseases, as well as one of the leading risk factors for cardio-cerebrovascular diseases. Tianma Gouteng decoction has been commonly used in clinical practice for patients with essential hypertension. It is important to update the search and evaluation to provide the best available evidence for essential hypertension. Here, we provide a protocol to evaluate the efficacy and safety of Tianma Gouteng decoction (TGD) for essential hypertension. METHODS: Retrieve literature on the TGD treatment for essential hypertension in the databases including PubMed, Cochrane Library, EMBASE, Chinese Biomedical database (CBM), Chinese National Knowledge Infrastructure (CNKI), Wanfang database, and Chinese Science and Technology Periodical database (VIP) on computer. The literature to be collected will be those published from the time when the respective databases were established to January 2018. The therapeutic effects according to the blood pressure (BP) will be accepted as the primary outcomes. We will use RevMan V.5.3 software as well to compute the data synthesis carefully when a meta-analysis is allowed. RESULTS: This study will provide a high-quality synthesis of current evidence of TGD for essential hypertension from several aspects including BP, life quality, heart rate, and adverse events. CONCLUSION: The conclusion of our systematic review will provide evidence to judge whether TGD is an effective intervention for patient with essential hypertension. PROSPERO REGISTRATION NUMBER: PROSPERO CRD 42018082319.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Medicamentos de Ervas Chinesas/uso terapêutico
Hipertensão Essencial/tratamento farmacológico
[Mh] Termos MeSH secundário: Pressão Sanguínea/efeitos dos fármacos
Protocolos Clínicos
Frequência Cardíaca/efeitos dos fármacos
Seres Humanos
Qualidade de Vida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Drugs, Chinese Herbal); 0 (tianma gouteng)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009972


  3 / 57391 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29329002
[Au] Autor:Durdagi S; Aksoydan B; Erol I; Kantarcioglu I; Ergun Y; Bulut G; Acar M; Avsar T; Liapakis G; Karageorgos V; Salmas RE; Sergi B; Alkhatib S; Turan G; Yigit BN; Cantasir K; Kurt B; Kilic T
[Ad] Endereço:Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahcesehir University (BAU), Istanbul, Turkey; Neuroscience Program, Graduate School of Health Sciences, Bahcesehir University, Istanbul, Turkey. Electronic address: serdar.durdagi@med.bau.edu.t
[Ti] Título:Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cell proliferation.
[So] Source:Eur J Med Chem;145:273-290, 2018 Feb 10.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:AT1 antagonists is the most recent drug class of molecules against hypertension and they mediate their actions through blocking detrimental effects of angiotensin II (A-II) when acts on type I (AT1) A-II receptor. The effects of AT1 antagonists are not limited to cardiovascular diseases. AT1 receptor blockers may be used as potential anti-cancer agents - due to the inhibition of cell proliferation stimulated by A-II. Therefore, AT1 receptors and the A-II biosynthesis mechanisms are targets for the development of new synthetic drugs and therapeutic treatment of various cardiovascular and other diseases. In this work, multi-scale molecular modeling approaches were performed and it is found that oxazolone and imidazolone derivatives reveal similar/better interaction energy profiles compared to the FDA approved sartan molecules at the binding site of the AT1 receptor. In silico-guided designed hit molecules were then synthesized and tested for their binding affinities to human AT1 receptor in radioligand binding studies, using [ I-Sar -Ile ] AngII. Among the compounds tested, 19d and 9j molecules bound to receptor in a dose response manner and with relatively high affinities. Next, cytotoxicity and wound healing assays were performed for these hit molecules. Since hit molecule 19d led to deceleration of cell motility in all three cell lines (NIH3T3, A549, and H358) tested in this study, this molecule is investigated in further tests. In two cell lines (HUVEC and MCF-7) tested, 19d induced G2/M cell cycle arrest in a concentration dependent manner. Adherent cells detached from the plates and underwent cell death possibly due to apoptosis at 19d concentrations that induced cell cycle arrest.
[Mh] Termos MeSH primário: Anti-Hipertensivos/farmacologia
Antineoplásicos/farmacologia
Descoberta de Drogas
Canais de Potássio Éter-A-Go-Go/antagonistas & inibidores
Imidazóis/farmacologia
Oxazolona/farmacologia
[Mh] Termos MeSH secundário: Animais
Anti-Hipertensivos/síntese química
Anti-Hipertensivos/química
Antineoplásicos/síntese química
Antineoplásicos/química
Pontos de Checagem do Ciclo Celular/efeitos dos fármacos
Morte Celular/efeitos dos fármacos
Proliferação Celular/efeitos dos fármacos
Células Cultivadas
Relação Dose-Resposta a Droga
Ensaios de Seleção de Medicamentos Antitumorais
Canais de Potássio Éter-A-Go-Go/metabolismo
Seres Humanos
Imidazóis/síntese química
Imidazóis/química
Camundongos
Modelos Moleculares
Estrutura Molecular
Células NIH 3T3
Oxazolona/síntese química
Oxazolona/química
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Antineoplastic Agents); 0 (Ether-A-Go-Go Potassium Channels); 0 (Imidazoles); 0 (KCNH1 protein, human); 0 (imidazolone); 15646-46-5 (Oxazolone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE


  4 / 57391 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29289256
[Au] Autor:Edriss H; Selvan K; Denega T; Rodrigues T; Test V; Nugent K
[Ad] Endereço:Department of Pulmonary and Critical Care Medicine, Texas Tech University Health Science Center, Lubbock, Texas. Electronic address: Hawa.edriss@ttuhsc.edu.
[Ti] Título:The Complexity of Characteristics, Diagnoses and Treatment of Older Patients With Pulmonary Hypertension.
[So] Source:Am J Med Sci;355(1):13-20, 2018 Jan.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Older patients with pulmonary hypertension (PH) are more likely to have complex comorbidity than younger patients with pulmonary arterial hypertension (PAH). The best approach to the evaluation and management of these patients is unclear. METHODS: We, retrospectively, reviewed the clinical records of patients older than 60 years referred for evaluation for PAH. We recorded patient demographics, comorbidity, functional classification (FC), right heart catheterization data, echocardiographic data, chest radiographic images and pulmonary function results. We recorded the final diagnoses according to World Health Organization (WHO) subgroups and treatment outcomes based on changes in FC. RESULTS: Ninety-seven records were reviewed in detail. The mean age was 71.2 ± 7.5 years with 66% women. Cardiovascular disease was the most frequent comorbidity. Mean PA pressure by catheterization was 39.5 ± 12.2mmHg (n = 65). The overall distribution after evaluation included 21 (21.6%) Group 1, 35 (36.1%) Group 2, 16 (16.5%) Group 3, 18 (18.6%) mixed Group 2 and 3, 6 (6.2%) Group 4 and 1 (1%) Group 5 patients. Group 1 patients were treated with PAH specific drug, and 12 patients had an improvement in FC with treatment. CONCLUSIONS: Older patients with suspected PH often have significant cardiovascular and respiratory comorbidity. Comprehensive evaluations are needed to determine the severity of PH and associated diseases and to initiate treatment focused on FC. Patients in WHO Group 2 and mixed Group 2 and 3 were frequently identified and constituted a diagnostic and treatment challenge in this study. Older patients with PAH may benefit from PAH specific drugs.
[Mh] Termos MeSH primário: Hipertensão Pulmonar/diagnóstico por imagem
Hipertensão Pulmonar/terapia
[Mh] Termos MeSH secundário: Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Anti-Hipertensivos/uso terapêutico
Bases de Dados Factuais
Feminino
Seres Humanos
Hipertensão Pulmonar/classificação
Masculino
Meia-Idade
Testes de Função Respiratória/métodos
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180101
[St] Status:MEDLINE


  5 / 57391 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29208265
[Au] Autor:Chaubal T; Bapat R
[Ad] Endereço:Department of Periodontics, D.Y.Patil University School of Dentistry, Nerul, Navi Mumbai, Maharashtra, India. Electronic address: tanayvc@gmail.com.
[Ti] Título:Mulberry-Shaped Gingival Overgrowth Induced by Amlodipine and Cyclosporine.
[So] Source:Am J Med Sci;354(6):e13, 2017 Dec.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anlodipino/efeitos adversos
Anti-Hipertensivos/efeitos adversos
Ciclosporina/efeitos adversos
Crescimento Excessivo da Gengiva/induzido quimicamente
Crescimento Excessivo da Gengiva/diagnóstico
Imunossupressores/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Anlodipino/administração & dosagem
Anti-Hipertensivos/administração & dosagem
Ciclosporina/administração & dosagem
Quimioterapia Combinada
Feminino
Seres Humanos
Imunossupressores/administração & dosagem
Transplante de Rim/tendências
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Immunosuppressive Agents); 1J444QC288 (Amlodipine); 83HN0GTJ6D (Cyclosporine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE


  6 / 57391 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29181932
[Au] Autor:Aambø A; Klemsdal TO
[Ti] Título:Cardiovascular disease and diabetes in patients with African or Asian background.
[Ti] Título:Kardiovaskulær sykdom og diabetes ved afrikansk eller asiatisk bakgrunn..
[So] Source:Tidsskr Nor Laegeforen;137(22), 2017 11 28.
[Is] ISSN:0807-7096
[Cp] País de publicação:Norway
[La] Idioma:eng; nor
[Ab] Resumo:BACKGROUND: Population groups of different ancestry appear to have varying prevalence of diabetes, different risks of developing cardiovascular disease and different responses to certain drugs that are used for these conditions. We wished to review the literature in this field. MATERIAL AND METHOD: We have performed searches in several databases for systematic review articles published from the year 2000 onwards, and supplemented these with articles from reference lists, our own literature archives and a pyramid search in the Norwegian Electronic Health Library database. Altogether 37 articles were included. RESULTS: With regard to diagnosed diabetes, the prevalence of coronary heart disease and stroke varies among groups of South Asian, East Asian, African and European ancestry. In patients of South Asian ancestry, the risk of coronary heart disease appears to be twice that of Europeans, and the disease occurs 5­10 years earlier. The prevalence of stroke is especially high in persons of African ancestry. Risk factors such as dyslipidemia and hypertension are distributed differently among these groups. The therapeutic response to drugs such as beta blockers, ACE inhibitors and various statins differs; for example, statin doses in Asians may often be halved in relation to those used for Caucasians, and ACE inhibitors are not recommended as monotherapy for hypertension in persons of African ancestry. These differences are partly attributable to variations in genetic disposition. INTERPRETATION: The findings are clinically significant ­ better insight in this field enables optimal tailoring of treatment for each patient, with more rapid achievement of goals and reduced risk of adverse effects. The recommendations given in this article are consistent with and complement the Directorate of Health's revised guidelines for the treatment of diabetes.
[Mh] Termos MeSH primário: Grupo com Ancestrais do Continente Africano/genética
Anti-Hipertensivos/farmacologia
Grupo com Ancestrais do Continente Asiático/genética
Doenças Cardiovasculares/etnologia
Diabetes Mellitus/etnologia
Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia
[Mh] Termos MeSH secundário: Anti-Hipertensivos/administração & dosagem
Doenças Cardiovasculares/tratamento farmacológico
Doenças Cardiovasculares/epidemiologia
Diabetes Mellitus/tratamento farmacológico
Diabetes Mellitus/epidemiologia
Grupo com Ancestrais do Continente Europeu/genética
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem
Farmacogenética
Acidente Vascular Cerebral/tratamento farmacológico
Acidente Vascular Cerebral/epidemiologia
Acidente Vascular Cerebral/etnologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.4045/tidsskr.16.0680


  7 / 57391 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390309
[Au] Autor:Takase H; Tanaka T; Takayama S; Nonaka D; Machii M; Sugiura T; Yamashita S; Ohte N; Dohi Y
[Ad] Endereço:Department of Internal Medicine, Enshu Hospital, Hamamatsu.
[Ti] Título:Recent changes in blood pressure levels, hypertension prevalence and treatment rates, and the rate of reaching target blood pressure in the elderly.
[So] Source:Medicine (Baltimore);96(50):e9116, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Antihypertensive treatment has beneficial effects in the elderly. Surveying the situation of blood pressure in the elderly is quite important for planning strategies to manage elderly hypertensives. The aim of the present study was to investigate changes in blood pressure in the elderly over the past 15 years.As part of a physical check-up program between 2001 and 2015, 29,363 elderly participants (≥65 years of age) attended and were enrolled in the present study. The characteristics of the participants in each year were analyzed cross-sectionally and the results were compared over the 15 years. Changes in blood pressure, hypertension prevalence, and treatment rates, and the rate of reaching target blood pressure in the elderly were investigated.The prevalence of hypertension during the study period increased with increasing participant age. However, both the treatment rate and the rate of reaching target blood pressure in treated subjects improved. The blood pressure of treated hypertensive elderly subjects decreased from 146.1/83.0 to 130.6/75.4 mm Hg, and the reduction was most evident after revision of Japanese Society of Hypertension guidelines regarding target blood pressure in elderly hypertensives. Blood pressure in the entire cohort of elderly subjects decreased from 133.8/78.4 mm Hg in 2001 to 127.9/74.6 mm Hg in 2015.Blood pressure in elderly subjects had decreased over the 15-year study period primarily due to reductions in blood pressure in elderly hypertensive patients on medication. Guidelines for the treatment of hypertension have had a beneficial effect on the management of hypertension in the elderly.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Hipertensão/tratamento farmacológico
Hipertensão/epidemiologia
[Mh] Termos MeSH secundário: Idoso
Determinação da Pressão Arterial
Estudos Transversais
Feminino
Seres Humanos
Masculino
Meia-Idade
Prevalência
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009116


  8 / 57391 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460758
[Au] Autor:Al-Nimer MSM; Hussein II
[Ad] Endereço:Department of Pharmacology, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq. Electronic address: alnimermarwan@ymail.com.
[Ti] Título:Subclinical ventricular repolarization abnormality in uncontrolled compared with controlled treated hypertension.
[So] Source:Indian Heart J;69(2):136-140, 2017 Mar - Apr.
[Is] ISSN:0019-4832
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Antihypertensive medications have variable effects on the duration of the QT interval. This study aims to demonstrate the subclinical ventricular conduction defect in treating hypertensive patients taking in consideration the status of the blood pressure control with the antihypertensive agents. METHODS: This cross-section study was performed at the Departments of Physiology and Pharmacology, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq. A total number of 97 hypertensive patients (30 males and 67 females) were eligible to enroll in the study. The patients were grouped into controlled hypertension (Group I) and uncontrolled hypertension (Group II). Each participant is subjected to the electrocardiograph (ECG) investigation. A QT nomogram plot used to identify the patients who are vulnerable or at risk of developing cardiac arrhythmias. RESULTS: There were no significant differences in the values of the electrocardiogram determinants between Group I and Group II. Abnormal prolonged QTcB interval observed in 18 out of 80 (22.5%) patients of Group II compared with 4 out of 17. The JT index value of ≥112 was observed in 20 out of 80 (25%) patients of Group II compared with 6 out of 17 (35.3%) patients of Group I. A significant correlation between the QTcB duration with JT index observed in both Groups I and II. CONCLUSION: Patients with hypertension have variability in ventricular repolarization (QTcB and JT) irrespective of their blood pressure control putting them at higher risk of cardiac arrhythmias.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Arritmias Cardíacas/fisiopatologia
Eletrocardiografia
Sistema de Condução Cardíaco/fisiopatologia
Frequência Cardíaca/fisiologia
Ventrículos do Coração/fisiopatologia
Hipertensão/fisiopatologia
[Mh] Termos MeSH secundário: Idoso
Arritmias Cardíacas/etiologia
Estudos Transversais
Feminino
Seguimentos
Ventrículos do Coração/inervação
Seres Humanos
Hipertensão/complicações
Hipertensão/tratamento farmacológico
Masculino
Meia-Idade
Estudos Retrospectivos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  9 / 57391 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29269696
[Au] Autor:Yokoi K; Ando T; Kawakami O
[Ad] Endereço:Department of Neurology, Anjo Kosei Hospital.
[Ti] Título:[Case of posterior reversible encephalopathy syndrome caused by Fisher syndrome].
[So] Source:Rinsho Shinkeigaku;58(1):45-48, 2018 Jan 26.
[Is] ISSN:1882-0654
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:This report presents a case of a 71-year-old woman with Fisher syndrome who had posterior reversible encephalopathy syndrome (PRES) before the initiation of intravenous immunoglobulin (IVIg) treatment. She had symptoms of common cold 2 weeks before the onset of PRES. On the day of the onset, she began to stagger while walking. On day 2, she developed hypertension, vision impairment, and limb weakness and was admitted to the hospital. On day 3, she was provided steroid pulse therapy. On day 4, she developed convulsions and right imperfection single paralysis and was transferred to the our hospital. During the transfer, the patient was conscious. Her blood pressure was high at 198/107 mmHg. She had mild weakness in her limbs and face, light perception in both eyes, dilation of both pupils, total external ophthalmoplegia, no tendon reflexes, and limb and trunk ataxia. We diagnosed PRES because of the high signal intensities observed on T -weighted MRI on both sides of the parietal and occipital lobes. We also diagnosed Fisher syndrome because of a positive anti-GQ1b immunoglobulin G antibody test and albuminocytologic dissociation in the cerebrospinal fluid. PRES showed prompt improvement with antihypertensive therapy, whereas Fisher syndrome slowly improved over a course of 2 months. This case is the first report of PRES without IVIg suggesting that Fisher syndrome induces hypertension and causes PRES.
[Mh] Termos MeSH primário: Síndrome de Miller Fisher/complicações
Síndrome da Leucoencefalopatia Posterior/etiologia
[Mh] Termos MeSH secundário: Idoso
Anti-Hipertensivos/administração & dosagem
Biomarcadores/sangue
Biomarcadores/líquido cefalorraquidiano
Proteínas do Líquido Cefalorraquidiano/líquido cefalorraquidiano
Diltiazem/administração & dosagem
Feminino
Gangliosídeos/imunologia
Seres Humanos
Imunoglobulina G/sangue
Imunoglobulinas Intravenosas
Imagem por Ressonância Magnética
Síndrome de Miller Fisher/diagnóstico
Neuroimagem
Síndrome da Leucoencefalopatia Posterior/diagnóstico por imagem
Síndrome da Leucoencefalopatia Posterior/tratamento farmacológico
Resultado do Tratamento
Valsartana/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Biomarkers); 0 (Cerebrospinal Fluid Proteins); 0 (Gangliosides); 0 (Immunoglobulin G); 0 (Immunoglobulins, Intravenous); 68652-37-9 (GQ1b ganglioside); 80M03YXJ7I (Valsartan); EE92BBP03H (Diltiazem)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171223
[St] Status:MEDLINE
[do] DOI:10.5692/clinicalneurol.cn-001089


  10 / 57391 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29470459
[Au] Autor:Fang J; Gillespie C; Ayala C; Loustalot F
[Ad] Endereço:Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC.
[Ti] Título:Prevalence of Self-Reported Hypertension and Antihypertensive Medication Use Among Adults Aged ≥18 Years - United States, 2011-2015.
[So] Source:MMWR Morb Mortal Wkly Rep;67(7):219-224, 2018 Feb 23.
[Is] ISSN:1545-861X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hypertension, which affects nearly one third of adults in the United States, is a major risk factor for heart disease and stroke (1), and only approximately half of those with hypertension have their hypertension under control (2). The prevalence of hypertension is highest among non-Hispanic blacks, whereas the prevalence of antihypertensive medication use is lowest among Hispanics (1). Geographic variations have also been identified: a recent report indicated that the Southern region of the United States had the highest prevalence of hypertension as well as the highest prevalence of medication use (3). Using data from the Behavioral Risk Factor Surveillance System (BRFSS), this study found minimal change in state-level prevalence of hypertension awareness and treatment among U.S. adults during the first half of the current decade. From 2011 to 2015, the age-standardized prevalence of self-reported hypertension decreased slightly, from 30.1% to 29.8% (p = 0.031); among those with hypertension, the age-standardized prevalence of medication use also decreased slightly, from 63.0% to 61.8% (p<0.001). Persistent differences were observed by age, sex, race/ethnicity, level of education, and state of residence. Increasing hypertension awareness, as well as increasing hypertension control through lifestyle changes and consistent antihypertensive medication use, requires diverse clinical and public health intervention.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Hipertensão/tratamento farmacológico
Hipertensão/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Feminino
Seres Humanos
Masculino
Meia-Idade
Prevalência
Autorrelato
Estados Unidos/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180223
[St] Status:MEDLINE
[do] DOI:10.15585/mmwr.mm6707a4



página 1 de 5740 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde